Phenacyl group containing amide derivative of dehydroabietylamine exhibiting enhanced cytotoxic activity against PLC and MCF7 cancer cell lines

Mustufa M. A., Aslam A., Ozen C., Hashmi I. A., Naqvi N. u. H., Ozturk M., ...More

MEDICINAL CHEMISTRY RESEARCH, vol.26, no.7, pp.1367-1376, 2017 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1007/s00044-017-1859-0
  • Journal Name: MEDICINAL CHEMISTRY RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1367-1376
  • Keywords: Cancer, Dehydroabietylamine, Amides, Cytotoxic activity, NMR spectroscopy, FTIR, CARBOXYLIC-ACIDS, ENDOCANNABINOIDS, ANALOGS, ASSAY
  • Dokuz Eylül University Affiliated: Yes

Abstract

New amide derivatives of (+)-dehydroabietylamine, tricyclic abietane diterpene amine, were prepared using Zhongping's protocol. (+)-N-(2-phenyl-acetyl)-dehydroabietylamine derivative (11) demonstrated noticeable growth attenuation of hepatocellular carcinoma cell lines including PLC/PRF/5, SNU475, Hep3B-TR, and Huh7 with IC50 of 7.4 A mu M, 9.8 A mu M, 11.7 A mu M, and 11.8 A mu M, respectively. A breast cancer cell line MCF7 was the most sensitive against amide 11 with lowest IC50 value (4.8 A mu M). Low cell confluence and increase in G2/M phase was recorded after 48 and 72 h of treatment of amide 11 on PLC/PRF/5 cell line. Finally, amide 11 has comparatively sufficient therapeutic role due to addition of N-phenacyl group at C-18. Amide 11 demonstrated as potential candidate for future cancer interference and research.